Skip to main content
BIAF
NASDAQ Industrial Applications And Services

bioAffinity Technologies Appoints Nationally Recognized Experts to Medical and Scientific Advisory Board

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$0.865
Mkt Cap
$4.049M
52W Low
$0.693
52W High
$46.53
52W Position info
25% above low
Off High info
98% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

BIAF sits 25% above its 52-week low of $0.693.

Summary

bioAffinity Technologies announced the appointment of three nationally recognized experts in pulmonary medicine and lung cancer to its Medical and Scientific Advisory Board, aiming to strengthen guidance for its CyPath Lung diagnostic test.


Key Events · Executive and Board Changes · BIAF

  • New Advisory Board Appointments

    David Ost, MD, MPH, Daniel Sterman, MD, and J. Scott Ferguson, MD, have been appointed to the Medical and Scientific Advisory Board.

  • Expertise in Pulmonary and Lung Cancer

    The new members are nationally recognized leaders in interventional pulmonology, thoracic oncology, critical care, and advanced diagnostic techniques for lung cancer.

  • Strategic Alignment for CyPath Lung

    The appointments aim to provide independent guidance on strategic priorities, including growing the adoption of the company's noninvasive CyPath Lung diagnostic test.


Analysis · BIAF · Industrial Applications And Services

bioAffinity Technologies, a biotechnology company focused on lung cancer diagnostics, has significantly strengthened its Medical and Scientific Advisory Board with the appointment of three highly respected experts in pulmonary medicine and lung cancer. These appointments are crucial for the company as it seeks to integrate its noninvasive CyPath Lung diagnostic test into the standard of care. The expertise of Drs. Ost, Sterman, and Ferguson in interventional pulmonology, thoracic oncology, and advanced diagnostic techniques will provide invaluable guidance for the clinical, scientific, and commercial priorities of CyPath Lung, potentially accelerating its adoption and market penetration.

At the time of this filing, BIAF was trading at $0.87 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $4M. The 52-week trading range was $0.69 to $46.53. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BIAF - Latest Insights

BIAF
Jul 07, 2026, 9:03 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $0.8401
Real-time Price: $0.6024 info
Change: -$0.2377 (-28%) info
Market Cap: $3.948M info
BIAF
Jul 07, 2026, 8:54 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.8355
Real-time Price: $0.6024 info
Change: -$0.2331 (-28%) info
Market Cap: $3.948M info
BIAF
Jun 30, 2026, 5:23 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $0.830
Real-time Price: $0.6024 info
Change: -$0.2276 (-27%) info
Market Cap: $3.948M info
BIAF
Jun 30, 2026, 5:19 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.830
Real-time Price: $0.6024 info
Change: -$0.2276 (-27%) info
Market Cap: $3.948M info
BIAF
Jun 18, 2026, 5:13 PM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $0.8389
Real-time Price: $0.6024 info
Change: -$0.2365 (-28%) info
Market Cap: $3.948M info